The arrival of biosimilar monoclonal antibodies in oncology: clinical studies for trastuzumab biosimilars

The monoclonal antibody trastuzumab (Herceptin®), which targets the human epidermal growth factor receptor 2 (HER2), is approved for the treatment of early breast and advanced breast and gastric cancer in which HER2 is overexpressed. Several biosimilar versions of trastuzumab are expected to enter t...

Full description

Saved in:
Bibliographic Details
Published in:Br J Cancer
Main Authors: Barbier, Liese, Declerck, Paul, Simoens, Steven, Neven, Patrick, Vulto, Arnold G., Huys, Isabelle
Format: Artigo
Language:Inglês
Published: Nature Publishing Group UK 2019
Subjects:
Review Article
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC6738325/
https://ncbi.nlm.nih.gov/pubmed/31257362
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41416-019-0480-z
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items